SML2897
Flomoxef Sodium
≥97% (HPLC)
别名:
(6R,7R)-7-[[2-[(Difluoromethyl)thio]acetyl]amino]-3-[[[1-(2-hydroxyethyl)-1H-tetrazol-5-yl]thio]methyl]-7-methoxy-8-oxo-5-oxa-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid monosodium salt, 6315-S Sodium salt, FMOX Sodium salt
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
H2O: 2 mg/mL, clear
storage temp.
−20°C
Quality Level
Biochem/physiol Actions
Flomoxef is a semisynthetic oxacephem antibiotic. Flomoxef exhibit activity against epidermides, streptococci, propionibacteria, and both methicillin-resistant and -susceptible Staphylococcus aureus. Flomoxef appear to be stable to the common plasmid beta-lactamases TEM and SH4V-1 or by the betalactamases of S. aureus or B. fragilis.
semisynthetic oxacephem antibiotic that is stable to the common plasmid beta-lactamases TEM and SH4V-1
存储类别
11 - Combustible Solids
wgk
WGK 3
法规信息
新产品
此项目有
Chen-Hsiang Lee et al.
Infection and drug resistance, 11, 2471-2480 (2018-12-21)
Flomoxef is potentially effective against β-lactamase-producing Enterobacteriaceae because limited clinical data demonstrate its effectiveness against Enterobacteriaceae bloodstream infections (BSIs) based on its minimum inhibitory concentrations (MICs). This study was conducted to determine the optimal breakpoints based on the survival of
H C Neu et al.
Antimicrobial agents and chemotherapy, 30(5), 638-644 (1986-11-01)
6315-S, a novel difluoromethyl thioacetamido oxacephem, had in vitro activity comparable to that of cefotaxime and moxalactam against Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, Klebsiella oxytoca, Citrobacter diversus, Salmonella spp., and Shigella spp., inhibiting 90% at less than or equal
Jen-Jia Yang et al.
Journal of microbiology, immunology, and infection = Wei mian yu gan ran za zhi, 51(5), 681-687 (2017-07-12)
Suppression of intestinal flora by broad-spectrum antimicrobial agents facilitated risk of colonization or infection with resistant pathogen. We aimed to investigate the changes in bowel carriage of target resistant microorganisms (TRO) among patients treated with three different classes of Pseudomonas-sparing
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持